- Close date
- No date set
- Academic background
- Health Sciences, Sciences
- Host campus
- Postgraduate Diploma, Master's, Honours
- Pathology (Dunedin)
- Dr Glen Reid, Dr Cath Drummond
Mutant forms of the oncogene KRAS are common drivers of non-small cell lung cancers (NSCLC).
Recently, sotorasib and adagrasib – targeted agents that specifically inhibit the KRASG12C mutant – have been approved for treating patients. Unfortunately, while many respond to this therapy, resistance invariably occurs.
This project will investigate how variable KRAS expression levels in different subpopulations of NSCLC cells contribute to their initial survival when treated with KRAS inhibitors.
Similar research opportunities
- A phoenix from the ashes: Do dying cancer cells induce drug-tolerance in lung cancer?
- A role for untranslated p53 mRNA in drug resistance
- Characterisation of YB-1 interactions with the cytoskeleton using live cell imaging
- Characteristion of YB-1 interactions with the cytoskeleton using live cell imaging
- Comprehensive characterization of uncommon TP53 mutations in cancer